Medline (MDLN) Q4 2025 earnings review
Double-Digit Growth Clouded by Tariff-Driven Margin Collapse
In its first earnings release as a public company, Medline delivered a stark divergence between top-line momentum and bottom-line reality. While Q4 net sales surged 14.8% to $7.8 billion, net income plummeted 37.7% to $180 million. The culprit is clear: a 19.1% spike in the cost of goods sold, driven heavily by tariffs, which crushed gross margins by 270 basis points. While the balance sheet looks vastly improved post-IPO (Net Leverage dropped from 4.9x to 3.1x), the core profitability engine is misfiring, with FY26 guidance implying only anemic ~2.4% EBITDA growth despite 8-9% expected sales growth.
🐂 Bull Case
The scale advantage is clear. Q4 Organic Sales accelerated to 14.4% growth, capped by a massive $2.4 billion in total new customer signings for the year. The Supply Chain Solutions segment is accelerating rapidly with 17.6% revenue growth.
IPO proceeds fundamentally repaired the balance sheet. Total debt was slashed by $4 billion, cash surged to $1.9 billion, and Net Leverage dropped aggressively from 4.9x to a much safer 3.1x.
🐻 Bear Case
Q4 Gross Margin fell from 27.3% to 24.6% as tariff impacts flowed through inventory to the P&L. Management's inability to pass these costs through pricing raises structural profitability concerns.
The high-margin Medline Brand segment saw operating leverage reverse. Despite an 11.8% sales increase, the segment's Adjusted EBITDA fell 3.8% in Q4, signaling deep cost-structure issues.
⚖️ Verdict: ⚪
Neutral. The volume growth and customer acquisition metrics are undeniably impressive, but the bottom line is structurally impaired by tariffs and operating costs. Until management proves they can protect margins, the stock's upside will be capped by poor earnings conversion.
Key Themes
Gross Margin Reversing Due to Tariffs
A severe macro headwind materialized in Q4: Cost of Goods Sold (+19.1%) vastly outpaced revenue growth (+14.8%). Management directly cited tariffs as the primary driver. This caused overall Gross Margin to compress from 27.3% a year ago to 24.6%. The fact that a distributor and manufacturer of this scale could not adjust pricing fast enough to offset government-imposed import policies is a major red flag for near-term profitability.
Supply Chain Solutions Accelerating
While the product side struggled with margins, the logistics engine thrived. Supply Chain Solutions segment sales grew 17.6% YoY to $4.06 billion in Q4. More importantly, it achieved excellent operating leverage, with segment Adjusted EBITDA surging 29.2% and margins expanding from 4.9% to 5.3%. This validates the stickiness and operational value of Medline's distribution footprint.
Medline Brand Profitability Collapse
The Medline Brand segment—traditionally the company's profit engine—is showing alarming deterioration. Despite healthy 11.8% revenue growth in Q4 ($3.72 billion), the segment's Adjusted EBITDA actually shrank by 3.8%. The segment margin plummeted from 24.8% down to 21.3%. This specific data point sharply contradicts the 'strong results' narrative in the press release.
Market Share Gains & Customer Signings
The company's core strategy of being the ultimate 'one-stop-shop' across the continuum of care is working. Medline secured $2.4 billion in total new customer signings in FY25. This expanding volume base provides a critical foundation for future cross-selling, assuming cost issues can be normalized.
Automation & Kitting Investments
CapEx increased 26.3% in FY25 to $447 million. Management explicitly linked this to continued enhancements and automation in their distribution centers and investments in kitting manufacturing facilities. While this dragged Free Cash Flow down slightly in the near term, deploying advanced supply-chain robotics is a necessary step to offset rising warehouse headcount and labor costs over the long run.
Working Capital Pressures
Free Cash Flow was decelerating, dropping 8.3% to $1.3 billion for the full year despite higher sales. This was driven by a heavy working capital burden: Inventories swelled by over $300 million to $4.76 billion (exacerbated by tariff impacts), and trade accounts receivable grew in line with sales. Efficient working capital management will be a key metric to monitor in 2026.
Other KPIs
Reversing sharply in a positive direction. Following the IPO, net debt was slashed by 34.7% (from $16.5B to $10.8B). Cash and equivalents ballooned to $1.9 billion from just $199 million a year ago. This dramatically reduces financial risk and lowers future interest expense burdens.
Stable. Down a marginal 1.4% from 2024. The cash conversion remains solid despite the massive drop in GAAP net income during Q4, largely because the net income drop was heavily influenced by non-cash inventory/LIFO adjustments ($83M for the year) and one-time IPO transaction costs.
Stable/Flat (-0.6% YoY). A stark disappointment given the nearly $1 billion increase in quarterly top-line revenue. Higher headcount investments and IPO-related expenses, combined with the tariff shock, entirely erased the margin benefit of scaling volumes.
Guidance
Decelerating. This marks a step down from the 10.5% organic growth achieved in FY25, and a notable slowdown from the 14.4% exit velocity seen in Q4 2025. It suggests management expects volume normalization or potential headwinds in market demand.
Stable, but fundamentally weak relative to top-line. The midpoint ($3.55B) implies just ~2.4% YoY growth compared to FY25's $3.467B. Because guided sales growth (8-9%) is roughly triple the guided EBITDA growth, management is explicitly signaling that Q4's margin compression (tariffs, labor) is a structural reality that will persist throughout 2026.
Key Questions
Tariff Mitigation Strategy
With gross margins compressing 270 basis points in Q4 primarily due to tariffs, what is the exact dollar headwind baked into the 2026 EBITDA guidance, and what specific levers (pricing, alternative sourcing) are you pulling to recapture those margins?
Medline Brand Profitability
The Medline Brand segment saw EBITDA decline 3.8% despite almost 12% revenue growth. How much of this was related to non-recurring IPO/headcount investments versus structural cost inflation, and when will this segment return to positive operating leverage?
Capital Expenditure ROI
CapEx grew 26% this year as you invested heavily in distribution center automation and kitting facilities. What is the expected payback period on these investments, and how much margin relief should we model from labor efficiency in 2026?